# BioNexus Gene Lab Corp: Form 10-Q for the period ended Jun 30, 2023

- Company: [BioNexus Gene Lab Corp](/companies/bglc.md) (CIK 1737523)
- Form: 10-Q
- Filed: 2023-08-16
- Accepted by EDGAR: Aug 16, 2023, 15:26 ET
- Period: 2023-06-30
- Accession: 0001477932-23-006208
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1737523/000147793223006208/bglc_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1737523/000147793223006208/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-04-01 to 2023-06-30 | $2.6m | us-gaap:Revenues |
| Revenue | 6 months, 2023-01-01 to 2023-06-30 | $4.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2023-04-01 to 2023-06-30 | $2.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2023-01-01 to 2023-06-30 | $4.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-04-01 to 2023-06-30 | $339.7k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2023-01-01 to 2023-06-30 | $708.6k | us-gaap:GrossProfit |
| Operating income | 3 months, 2023-04-01 to 2023-06-30 | −$272.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-01-01 to 2023-06-30 | −$322.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 6 months, 2023-01-01 to 2023-06-30 | $5.5k | us-gaap:InterestExpense |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | −$259.3k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | −$328.3k | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | −$140.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-01-01 to 2023-06-30 | $14.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-06-30 | $297.1k | us-gaap:Cash |
| Current assets | at 2023-06-30 | $5.2m | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $7.9m | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $1.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-06-30 | $6.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 26,162 characters.

### Description of Business

As used herein, unless the context otherwise indicates, references to the “Company,” “we,” “our,” “us,” “BioNexus” refer to BioNexus Gene Lab Corp., a Wyoming company (“BGLC”), and its wholly owned subsidiaries, Bionexus Gene Lab Sdn. Bhd. (“Bionexus Malaysia”), and Chemrex Corporation Sdn. Bhd. (“Chemrex”), both are Malaysian companies.

BGLC is an emerging molecular lab focused on the application of functional genomics to enable early detection of infectious diseases and cancers. On August 23, 2017, we acquired all of the outstanding capital stock of BioNexus Malaysia, which was incorporated in Malaysia on April 7, 2015. BioNexus Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which we use in our business. Our non-invasive blood screening tests analyze changes in ribonucleic acid (or RNA) to Coronavirus, Dengue, HIV, HPV and the risk potentiality of cancers diseases. This unique blood genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body currently.

The corporate and principal office address of the Company and BioNexus Malaysia is Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia., our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. Another lab focuses on Covid-19 and Colon cancer screening is located at 4th floor, Lifecare Diagnostic Centre, Kuala Lumpur, Malaysia. Our telephone number is (+60) 1221-26512 and our website is www.bionexusgenelab.com.

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

Chemrex’s corporate office and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and website is www.chemrex.com.my.

22

#### Table of Contents

The results of operations of our subsidiary, BioNexus-Malaysia, with respect to its RNA screening process have been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants, including Alpha, Beta, Delta, and Omicron. Although new variants are an expected part of the evolution of viruses, new variant is more aggressive, highly transmissible, vaccine-resistant, able to cause more severe disease in Malaysia. We believe that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff. Since our RNA screening is administered at a diagnostic center, our business has been adversely affected as a result.

The results of operations for Chemrex were adversely impacted during fiscal year 2023 and the 1st quarter of 2023 as businesses of Chemrex customers especially the manufacturers had suffered significant impact. Many of them across the country saw their supply chains interrupted, demand for their products and services decline, shortages in supplies and inputs.

Recent Developments.

We had proposed an annual $28m screening project to the Chief Secretary of the Health Ministry of Malaysia for a nationwide RNA screening on 0.2% of the population aged 40 and above. The Deputy Director General from Public Health met us on January 17, 2023 to examine the cost effectiveness of our RNA screening. While the Federal government is studying our proposal, the Sabah state government planned to allocate $2.5m to establish a lab in Kota Kinabalu, Sabah capital city for Bionexus-Malaysia to work with local hospitals and state insurance corporation. Meanwhile, we had presented our technology and expansion plan nationally and globally to the Minister of Science and Technology. We received favorable response, and were advised to submit for a $2m technology grant for the continuation of research, commercialization and expansion.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

|  | June 30, 2023 | December 31, 2022 |
| --- | ---: | ---: |
| Period ended June 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate | 4.6650 | 4.3900 |
|  | **January 1, 2023 to June 30, 2023** | **January 1, 2022 to June 30, 2022** |
| 6 months average US$1: MYR exchange rate | 4.4629 | 4,2710 |

23

#### Table of Contents

### Results of Operations

***Three Months Ended June 30, 2023 Compared with the Three Months Ended June 30, 2022.***

The following table sets forth key selected financial data for the three months ended June 30, 2023 and 2022.

### Consolidated

|  | Three months ended June 30, 2023 | 2022 |
| --- | ---: | ---: |
| REVENUE | $2,566,848 | $2,485,101 |
| COST OF REVENUE | (2,227,134) | (2,221,130) |
| GROSS PROFIT | 339,714 | 263,971 |
| OTHER INCOME | 195,164 | 52,848 |
| OPERATING EXPENSES |  |  |
| General and administrative | (807,077) | (454,783) |
| **LOSS FROM OPERATIONS** | **(272,199)** | **(137,964)** |
| FINANCE COSTS | (3,042) | (2,319) |
| **LOSS BEFORE TAX** | **(275,241)** | **(140,283)** |
| Tax expense | 15,990 | 1,621 |
| **NET LOSS** | **$(259,251)** | **$(138,662)** |
| Other comprehensive income: |  |  |
| Foreign currency loss | (333,891) | (317,760) |
| **COMPREHENSIVE LOSS** | **$(593,142)** | **$(456,422)** |

24

#### Table of Contents

### Segmented Information

|  | BioNexus Malaysia Three months ended June 30, 2023 | Chemrex | BioNexus Malaysia Three months ended June 30, 2022 | Chemrex |
| --- | ---: | ---: | ---: | ---: |
| REVENUE | $4,496 | $2,562,352 | $9,198 | $2,475,903 |
| COST OF REVENUE | (2,201) | (2,224,933) | (6,891) | (2,214,239) |
| **GROSS PROFIT** | 2,295 | 337,419 | 2,307 | 261,664 |
| OTHER INCOME | 1,039 | 194,125 | 2,209 | 50,639 |
| OPERATING EXPENSES |  |  |  |  |
| General and administrative | (52,465) | (642,719) | (50,639) | (320,579) |
| **LOSS FROM OPERATIONS** | (49,131) | (111,175) | (46,123) | (8,276) |
| FINANCE COSTS | (609) | (2,433) | (1,061) | (1,258) |
| **LOSS BEFORE TAX** | **(49,740)** | **(113,608)** | **(47,184)** | **(9,534)** |
| Tax expense | - | 15,990 | - | 1,621 |
| **NET LOSS** | **$(49,740)** | **$(97,618)** | **$(47,184)** | **$(7,913)** |

***Revenue.*** For the quarter ended June 30, 2023, we had total revenue of $2,566,848 as compared to total revenue of $2,485,101 for the quarter ended June 30, 2022, increased by 3.3% from the prior quarter due to slight increase in purchases from customers.

Chemrex contributed $2,562,352 (99.8%) of the total revenue for the current quarter ended June 30, 2023 as compared to $2,475,903 (99.6%) of the total revenue for the quarter ended June 30, 2022. Chemrex’s revenues had an increase by $86,449 of 3.5% from prior quarter. The revenue increased in second quarter of 2023 was due to increase in purchases from customers.

BioNexus-Malaysia contributed $4,496 (0.2%) of the total revenue for the quarter ended June 30, 2023 as compared to revenue of $9,198 (0.4%) of the total revenue from the quarter ended June 30, 2022. Revenues had decreased by $4,702 from prior quarter of $9,198, a 51.1% decrease due to six (6) long weekends public holidays during the second quarter resulting in fewer referrals from diagnostics centers & clinics.

***Cost of Revenue.*** For the quarter ended June 30, 2023, we incurred $2,227,134 in cost of revenues, as compared to $2,221,130 for the quarter ended June 30, 2022, a slight increase of 0.3% was due to reason as stated above.

Chemrex had incurred $2,224,933 (99.9%) of the total cost of revenue during the current quarter period ended June 30, 2023 as compared to the quarter ended June 30, 2022 wherein Chemrex had incurred $2,214,239 (99.7%) of the total cost of revenue. The slightly increase in Chemrex’s cost of revenues of 0.5% for the current period was due to its increased revenues and reason as stated above.

BioNexus had incurred $2,201 (0.1%) of the total cost of revenues during the current quarter period ended June 30, 2023 as compared to $6,891 (0.3%) for the quarterly period ended June 30, 2022. Cost of revenue had decreased by $4,690 from prior quarter of 68.1% decrease was due to its decreased revenues and reason as stated above.

25

#### Table of Contents

***Gross Profit.*** For the quarterly period ended June 30, 2023, we had total gross profit of $339,714 as compared to gross profit of $263,971 for the quarterly period ended June 30, 2022, an increase by approximately 28.7% from the prior period.

Chemrex contributed $337,419 (99.3%) of the total gross profit for the current quarter ended June 30, 2023 as compared to $261,664 (99.1%) of the total gross profit for the quarter ended June 30, 2022. Chemrex’s gross profit increased by $75,755 from the prior quarter, an approximately 29% increase. The gross profit increase for Chemrex in current quarter was due to an increase in revenue and reduced purchases prices reduced.

BioNexus-Malaysia contributed $2,295 (0.7%) of the total gross profit of $339,714 for the current quarter ended June 30, 2023 as compared to gross profit of $2,307 (0.9%) of the total gross profit from the quarter ended June 30, 2022. The decrease by approximately 0.5% from the prior period due to its decreased revenues for the same reason stated above.

***Other Income.*** For the quarterly period ended June 30, 2023, we had of $195,164, as compared to of $52,848 for the quarterly period ended June 30, 2022, an increase of approximately 269.3%.

Chemrex contributed $194,125 (99.5%) of other income for the current quarter ended June 30, 2023 as compared to $50,639 (95.8%) of the other income for the quarter ended June 30, 2022. Chemrex’s other income increased by 283.4% due to gain on forex exchange rate, gain on fair value of investment, bank interest earning and unrealized equity investment gain.

BioNexus-Malaysia contributed $1,039 (0.5%) of other income for the current quarter ended June 30, 2023 as compared to $2,209 (4.2%) of the other income for the quarter ended June 30, 2022. The decrease of 53% due to lesser fund in the fixed deposit resulted from a reduction in bank interest earning.

***Operating Expenses.*** For the quarter ended June 30, 2023, we had total operating expense of $807,077 as compared to total operating expenses of $454,783 for the quarter ended June 30, 2022, an increase by approximately 77.5%. It was due to general and administrative expenses which includes depreciation of fixed assets, employee compensation and benefits, professional fees for the Nasdaq uplisting and marketing and travel expenses.

Chemrex had incurred $642,719 (79.6%) of the total operating expenses for the current quarter ended June 30, 2023 as compared to $320,579 (70.5%) of the total operating expenses for the quarter ended June 30, 2022, an increase by 100.5%. The increase in operating expenses was due to debt consultant, directors’ remuneration, entertainment, upkeep of equipment, marketing website improvement and provision for losses on accounts receivable.

BioNexus-Malaysia had incurred $52,465 (6.5%) of the total operating expenses for the current quarter ended June 30, 2023 as compared to $50,639 (11.1%) of the total operating expenses for the quarter ended June 30, 2022, a slight increase by 3.6%. The increase in operating costs of the current quarter was due to Research and development cost incurred for patients with cardiovascular disease.

BGLC, the holding company had incurred $111,893 (13.9%) of total operating expenses for the current quarter ended June 30, 2023 as compared to $83,565 (18.4%) of the total operating expenses for the quarter ended June 30, 2022. The increase by approximately 33.9% in operating costs for the quarter ended June 30, 2023 was due to directors and committees’ fees, professional expenses and charges from Advisor, Attorney, STC (Transfer Agent), Finra, Nasdaq and SEC on the Company’s uplisting to Nasdaq.

***Loss/Profit from Operations.*** We had a loss from operations of $272,199 for the quarter ended June 30, 2023 as compared to a loss of $137,964 for the quarter ended June 30, 2022, an increase by approximately 97.3% from the prior period, for the reasons discussed above.

***Income tax expense.*** For the quarter ended June 30, 2023, we had adjustment of income tax credit of $15,990 as compared to tax credit of $1,621 for the quarter ended June 30, 2022 for Chemrex. There was no tax provision for Bio-Nexus Malaysia for the quarters ended June 30, 2023 and 2022.

***Foreign currency exchange loss.*** We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate would require us to recognize a transaction gain or loss on revaluation. For the three-month period ended June 30, 2023, we experienced a foreign currency loss of $333,891 as compared with a foreign currency loss of $317,760 for the three-month period ended June 30, 2022.

26

#### Table of Contents

### Six Months Ended June 30, 2023 Compared with the Six Months Ended June 30, 2022.

The following table sets forth key selected financial data for the six months ended June 30, 2023 and 2022.

### Consolidated

|  | Six months ended June 30, 2023 | 2022 |
| --- | ---: | ---: |
| REVENUE | $4,944,053 | $5,514,046 |
| COST OF REVENUE | (4,235,442) | (4,893,742) |
| GROSS PROFIT | 708,611 | 620,304 |
| OTHER INCOME | 312,508 | 99,230 |
| OPERATING EXPENSES |  |  |
| General and administrative | (1,343,949) | (822,807) |
| **LOSS FROM OPERATIONS** | (322,830) | (103,273) |
| FINANCE COSTS | (5,487) | (5,645) |
| **LOSS BEFORE TAX** | (328,317) | (108,918) |
| Tax expense | - | (12,678) |
| **NET LOSS** | $(328,317) | $(121,596) |
| Other comprehensive income: |  |  |
| Foreign currency translation loss | (372,930) | (386,536) |
| **COMPREHENSIVE LOSS** | $(701,247) | $(508,132) |

27

#### Table of Contents

### Segmented Information

|  | BioNexus Malaysia Six months ended June 30, 2023 | Chemrex | BioNexus Malaysia Six months ended June 30, 2022 | Chemrex |
| --- | ---: | ---: | ---: | ---: |
| REVENUE | $11,932 | $4,932,121 | $33,467 | $5,480,579 |
| COST OF REVENUE | (7,548) | (4,227,894) | (14,929) | (4,878,813) |
| GROSS PROFIT | 4,384 | 704,227 | 18,538 | 601,766 |
| OTHER INCOME | 2,165 | 310,343 | 4,285 | 94,945 |
| OPERATING EXPENSES |  |  |  |  |
| General and administrative | (98,720) | (1,025,896) | (94,681) | (618,348) |
| **(LOSS)/PROFIT FROM OPERATIONS** | **(92,171)** | **(11,326)** | **(71,858)** | **78,363** |
| FINANCE COSTS | (1,275) | (4,212) | (1,860) | (3,785) |
| **(LOSS)/PROFIT BEFORE TAX** | (93,446) | (15,538) | (73,718) | 74,578 |
| Tax expense | - | - | - | (12,678) |
| **NET (LOSS)/PROFIT** | $(93,446) | $(15,538) | $(73,718) | $61,900 |

***Revenue.*** For the six months period ended June 30, 2023, we had total revenue of $4,944,053 as compared to total revenue of $5,514,046 for the same period in 2022, which had decreased by $569,993 from the prior period, approximately 10.3% decrease.

Chemrex contributed $4,932,121 (99.8%) of the total revenue for the current six months period as compared to $5,480,579 (99.4%) of the total revenue for the same period last year. Chemrex’s revenues had decreased by $548,458 from prior period, approximately 10.01% decrease. The revenue decreased in 2023 was due to material cost for Resin & Fiberglass mat has been reduced in Malaysia since January 2023. As a result, we adjusted the selling price of our product to stay competitive. Chemrex is catching up with the markets change post pandemic by targeting the right manufacturers to reduce cost of logistics and warehousing meanwhile may scarify some small retail businesses.

BioNexus-Malaysia contributed $11,932 (0.2%) of the total revenue for the current six months period as compared to revenue of $33,467 (0.6%) of the total revenue from the same period last year. BioNexus’s revenue had decreased by $21,535 from prior quarter, an approximately 64.3% decrease. The revenue decrease in 2023 was due to RNA screening process having been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants, including Alpha, Beta, Delta, and Omicron. Although new variants are an expected part of the evolution of viruses, new variant is more aggressive, highly transmissible, vaccine-resistant, able to cause more severe disease in Malaysia. We believe that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff. Since our RNA screening is administered at a diagnostic center, our business had been adversely affected as a result.

***Cost of Revenue***. For the six months period ended June 30, 2023, we incurred $4,235,442 in cost of revenues, as compared to $4,893,742 for the same period in 2022, decreased by $658,300 approximately 13.5% decrease was due to the same reason stated above.

Chemrex had incurred $4,227,894 (99.8%) of the total cost of revenue during the current period as compared to the same period last year wherein Chemrex had incurred $4,878,813 (99.7%) of the total in cost of revenue, decreased by $650,919, approximately 13.34% was due to the same reason stated above.

BioNexus had incurred $7,548 (0.2%) of the total cost of revenues during the current period as compared to $14,929 (0.3%) for the same period in 2023, decreased by $7,381, approximately 49.4% in cost of revenues for the current period was due to the same reason stated above.

***Gross Profit.*** For the six months period ended June 30, 2023, we had total gross profit of $708,611 as compared to gross profit of $620,304 for the same period in 2023, increased by approximately 14.2% from the prior period.

Chemrex contributed $704,227 (99.4%) of the total gross profit for the current six months period as compared to $601,766 (97.0%) of the total gross profit for the same period last year. The gross profit increased by $102,461, approximately 17.3% for current period was due to higher revenue resulting higher gross profit.

28

#### Table of Contents

**BioNexus**-Malaysia had a gross profit of $4,384 (0.6%) of the total gross profit of $708,611 for the current six months period as compared to $18,538 (3%) of the total gross profit of $620,304 from the same period last year. The gross profit decreased by 76.4% was due to its decreased revenues for the current period as according to reason stated above.

***Other Income***. For the six months period ended June 30, 2023, we had $312,508 as compared to $99,230 for the same period in 2022, increased by $213,278 approximately 214.9%.

Chemrex contributed $310,343 (99.3%) of other income for the current six months period as compared to $94,945 (95.7%) of the other income for the same period last year. Chemrex’s other income increased by $215,398, approximately 226.87% was generated from bank interest and gain from fair value on investment.

BioNexus Malaysia had $2,165 (0.7%) for six months period ended June 30, 2023 as compared to $4,285 (4.3%) for the same period in 2022, decreased by approximately 49.5% was due to lower bank interest earning from lower fund deposited.

***Operating Expenses***. For the six months period ended June 30, 2023, we had a total operating expense of $1,343,949 as compared to total operating expenses of $822,807 for the same period in 2022. The increase of $521,142, approximately 63.3% was due to general and administrative expenses which includes depreciation of fixed assets, employee compensation and benefits, marketing/travel expenses, FINRA, SEC, Nasdaq and professional fees for Nasdaq uplist.

Chemrex had incurred $1,025,896 (76.3%) of the total operating expenses for the current six months period as compared to $618,348 (75.2%) of the total operating expenses for the same period last year, increased by $407,548, approximately 65.91% due to the increased commission, directors’ remuneration, medical expenses, loss on unrealized/realized currency exchanges and provision for losses on account receivables.

BioNexus-Malaysia had incurred $98,720 (7.3%) of the total operating expenses for the current six months period as compared to $94,681 (11.5%) of the total operating expenses for the same period last year. The slightly increase by approximately 4.3% in operating costs for the six months period was due to an increase of traveling expenses for marketing and staff remuneration increase.

BGLC, the holding company had incurred $219,333 (16.3%) of total operating expenses for the current six months period as compared to $109,778 (13.3%) of the total operating expenses for the same period last year. The increase of $109,555, approximately 99.8% in operating costs of the current period was due to the expenses on filing fees for form S-1, consultant fees for capital & corporation advisory services, fees for three independent board members and audit committee, SEC compliance services, SEC registration fee, 300+ shareholders’ notice printing and mailing expenses regarding stock reverse split by Securities Transfer Corporation, an additional review fee for S-1 and listing expenses for Nasdaq uplist.

***Profit/Loss from Operations***. We had a loss from operations of $322,830 for six months period ended June 30, 2023 as compared to loss of $103,273 for the same period in 2022. The decrease of $219,557, approximately 212.6% was due to the reasons discussed above.

*Income tax expense*. For the six-months period ended June 30, 2023, we had no income tax provided for Chemrex and Bionexus as compared to the same period 2022 which was a tax estimated $12,678 from Chemrex and no tax provided from Bionexus.

***Foreign currency exchange gain/(loss).*** We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate would require us to recognize a transaction gain or loss on revaluation. For the six-months period ended June 30, 2023, we experienced a foreign currency loss of $372,930 as compared with a foreign currency loss of $386,536 for the same period in 2022.

29

#### Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2023, we had working capital of $3,350,280 compared with working capital of $4,017,749 as of December 31, 2022. The decrease in working capital as of June 30, 2023 from December 31, 2022 was due principally to the decrease in cash used in our operations.

Our primary uses of cash had been for operations. The main sources of cash was generated from operational revenues and the private placement of our common stock. The following trends could result in a material decrease in our liquidity over the near to long term:

- Addition of administrative and marketing personnel as the business grows,
- Development of a Company website,
- Increases in advertising and marketing in order to attempt to generate more revenues, and
- The cost of being a public company.

The Company believes that cash flow from operations together will be sufficient to sustain its current level of operations for at least the next 12 months of operations.

The following is a summary of the Company’s cash flows provided by (used in) / generated from operating, investing, and financing activities for the three months ended June 30, 2023 and 2022:

|  | Six months ended June 30, 2023 | 2023 |
| --- | ---: | ---: |
| Net cash used in Operating Activities | $(140,341) | $(237,593) |
| Net cash used in investing activities | (8,114) | (418,955) |
| Net cash generated from/(used in) financing activities | (4,212) | 112,177 |
| Foreign currency translation adjustment | (207,517) | (243,002) |
| **Net Change in Cash and Cash Equivalents** | **$(360,184)** | **$(783,588)** |

#### Operating Activities

During the six months ended June 30, 2023, the Company incurred a net loss of $328,317 which, after adjusting for amortization, depreciation, dividend income, fair value gain on share investment, provision for losses on accounts receivable, an increase in inventories, a decrease in trade receivables and a substantial reduction in trade payables, operating lease liabilities, advance payment from customer, resulted in net cash of $40,341 being used in operating activities during the six months ended June 30, 2023.By comparison, during the six months ended June 30, 2022, the Company had a net loss of $121,596 after adjusting for amortization, depreciation, dividend income, fair value loss on share investments and a decrease in inventories, trade receivables, deferred cost of revenue, a substantial reduction in trade payables, operating lease liabilities, advance payment from customer, deferred revenue, resulted in net cash of $233,808 being used in operating activities during the period.

#### Investing Activities

During the six months ended June 30, 2023, the Company had net cash of $8,114 used in investment activities from acquisition of share investment of $13,444 and purchase of plant & equipment of $14,458. By comparison during the six months ended June 30, 2022, the Company had net cash from acquisition of share investment of $404,793 and purchase of plant and equipment of $33,484, resulting in net cash used in investing activities of $418,955.

#### Financing Activities

During the six month ended June 30, 2023, the Company had net cash of $4,212 used in financing activities. By comparison during the six months ended June 30, 2022, we had net cash of $112,177 generated from financing activities for continued the repayment of a finance lease of $34,038 and shares subscriptions of $150,000.

## Market risk

As filed, 173 characters.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this item.

30

#### Table of Contents

## Controls and procedures

As filed, 5,741 characters.

#### Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this quarterly report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of June 30, 2023. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were capable in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

#### Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

i) Pertain to the maintenance of records that is in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;

ii) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and the board of directors; and

iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management had assessed the effectiveness of our internal control over financial reporting as of June 30, 2023, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, which assessment identified material weaknesses in internal control over financial reporting had improved. A material weakness could create reasonable possibility that a material misstatement in annual or interim financial statements. The management considers its internal control over financial reporting required further improvement.

Management had concluded an internal control over financial reporting and glad to note that a majority of our Board of Directors was made up of independent directors and the Audit Committee comprised of all independent directors since 2023, the adequacy in the monitoring of required internal controls and procedures were improving.

While these control deficiencies did not result in any audit adjustments to our 2023 or 2022 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties.

To the extent reasonably possible, given our limited resources, upon consummation of a merger with a private operating company, the Company had been relying on three or more individuals. We were expanding our current board of directors to include additional independents willing to perform directorial functions. Since the recited remedial actions and we would hire or engage additional personnel, this material weakness would be overcome in the near term. Until such remedial actions could be realized, we would continue to rely on the advice of outside professionals and consultants.

This quarterly report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

### Changes in Internal Controls over Financial Reporting

During the period ended June 30, 2023, there had been no change in internal control over financial reporting that had materially affected or was reasonably likely to materially affect our internal control over financial reporting.

31

#### Table of Contents

Filed Aug 16, 2023.
Source: SEC EDGAR, the filing index for accession 0001477932-23-006208. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
